Research field (1):
Tumor diagnostics and therapeutics
Research theme for competitive and other funds (11):
2020 - 2023 Immunogenic cell death by cytotoxic agents
2019 - 2022 Establishment of monitoring method using cfDNA gene mutation profile in patients with malignant tumors
2017 - 2020 Personalized therapy targeting Met gene in lung cancer
2014 - 2017 Identification of Novel Treatment Targets and Biomarkers for Small-Cell Lung Cancer by Circulating Tumor Cell Analysis
2014 - 2017 Regulation of Topisomerase I activity by cMet in lung cancer
2014 - 2017 Analysis of predictive biomarker of Erlotinib to non-small cell lung cancer without EGFR mutation
2014 - 2016 血中循環癌細胞解析を利用した小細胞肺癌の新規治療標的・バイオマーカーの同定
2011 - 2012 VEGFR2 tyrosine kinase inhibitor (VEGFR2-TKI)-resistant cancer tissue from a cancer-bearing mouse model
2011 - 2012 Vivo耐性株による血管新生阻害薬耐性メカニズム
2008 - 2009 Detection of tumor-derived mutations in circulating DNA
2008 - 2009 血中DNAを用いた腫瘍特異的遺伝子変異の検出とその臨床的意義
Show all
Papers (190):
Hayato Koba, Taro Yoneda, Hiroko Morita, Hideharu Kimura, Yuya Murase, Nanao Terada, Yuichi Tambo, Masafumi Horie, Kazuo Kasahara, Isao Matsumoto, et al. Genomic evolutional analysis of surgical resected specimen to assess osimertinib as a first-line therapy in two patients with lung cancer harboring EGFR mutation: Case series. Thoracic Cancer. 2024
- 2006 Kanazawa University Graduate School, Division of Medicine
1992 - 1998 Kanazawa University
Committee career (2):
2016/12 - 現在 日本肺癌学会 バイオマーカー委員会
2014/11 - 現在 日本肺癌学会 ガイドラインー診断小委員会
Association Membership(s) (7):
日本臨床腫瘍学会
, THE JAPAN SOCIETY FOR RESPIRATORY ENDOSCOPY
, American Association for Cancer Research
, THE JAPANESE CANCER ASSOCIATION
, THE JAPAN LUNG CANCER SOCIETY
, THE JAPANESE RESPIRATORY SOCIETY
, THE JAPANESE SOCIETY OF INTERNAL MEDICINE